|
Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM). |
|
|
Research Funding - Abbvie (Inst); Celgene (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Celgene; Janssen; Takeda |
Research Funding - Celgene; Takeda |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen Oncology |
Speakers' Bureau - Amgen; Celgene; Takeda |
Research Funding - Array BioPharma; Celgene; Janssen Oncology; Millennium; Onyx; Pharmacyclics; Sanofi |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Merck; Novartis; Takeda |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Sanofi |
|
|
|
Stock and Other Ownership Interests - Sanofi |
|
|
|
Stock and Other Ownership Interests - Sanofi |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Millennium |
Patents, Royalties, Other Intellectual Property - C4 Therapeutics; Oncopep |